1. Home
  2. Universitat de Barcelona
  3. Economia
  4. View Item

A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Author

Darbà, Josep

Ramírez, Gabriela

García-Rivero, Juan L.

Mayoralas, Sagrario

Pascual, José Francisco

Roger, Albert

Vargas, Diego

Bijedic, Adi

Publication date

2017-03-02T15:37:24Z

2017-03-02T15:37:24Z

2016-09

2017-03-02T15:37:24Z

Share

Abstract

To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...

Document Type

Article

Published version

Language

English

Subjects and keywords

Administració de medicaments; Asma; Malalties pulmonars obstructives cròniques; Tractament tèrmic; Economia de la salut; Administration of drugs; Asthma; Chronic obstructive pulmonary diseases; Heat treatment; Medical economics

Publisher

Dove Medical Press

Related items

Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S111453

Clinicoeconomics and Outcomes Research, 2016, vol. 8 , p. 435-444

https://doi.org/10.2147/CEOR.S111453

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

cc-by-nc (c) Darbà, Josep et al., 2016

http://creativecommons.org/licenses/by-nc/3.0/es

This item appears in the following Collection(s)

Economia [1047]

ISGlobal - Institut de Salut Global de Barcelona [61348]